RxDoctor Payments Data

Christine Urbanski, MD

Hematology & Oncology · Delta, CONPI 1548201528

Payments from drug & device makers

$5,488in general payments, 2019–2025

Across 265 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$624
  • AstraZeneca$425
  • Johnson & Johnson$369
  • Incyte Corporation$348
  • Daiichi Sankyo Inc.$238
  • Merck$218
  • plus $3K from 50 others

What the payments were for

  • Food & beverage$5,19495%
  • Education$2955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,488 in reported general payments places this provider in the 40th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$47,896
Medicare patients
120
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate14$247,544
TagrissoOsimertinib Mesylate11$215,717
VerzenioAbemaciclib12$181,171
Abiraterone Acetate58$99,081
CreonLipase/Protease/Amylase11$29,045
Anastrozole70$1,215
Tamoxifen Citrate39$490
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$482
Gabapentin13$451
Letrozole18$450
Potassium Chloride22$326
Prochlorperazine Maleate28$285
Oxycodone Hcl13$261
Prednisone46$239
Lidocaine-PrilocaineLidocaine/Prilocaine14$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$624$247,54414 claims
AstraZenecaTagrisso$425$215,71711 claims
Lilly USA, LLCVerzenio$51$181,17112 claims
AbbVieCreon$81$29,04511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 169 hematology & oncology providers in Colorado.

Other hematology & oncology in Delta

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →